Levine A M
Division of Hematology, University of Southern California (USC), USC/Norris Cancer Hospital, Los Angeles 90033, USA.
J Natl Cancer Inst Monogr. 1998(23):37-42. doi: 10.1093/oxfordjournals.jncimonographs.a024171.
Although Hodgkin's disease (HD) is not usually associated with congenital or acquired immunodeficiency disorders, recent evidence would suggest a statistically significant increase in HD among individuals infected with human immunodeficiency virus (HIV). In the setting of underlying HIV infection, clinical and pathologic characteristics of HD may differ from usual expectations. Thus, 70%-100% of HIV-infected patients with HD present with systemic "B" symptoms. Likewise, disseminated, stage III or IV disease is reported in approximately 75%-90%. Bone marrow is a common site of extranodal HD, occurring in 40%-50%. Complete response rates after multiagent chemotherapy range from approximately 45% to 70%, although median survival has been only in the range of approximately 18 months. Hematologic toxicity from multiagent chemotherapy may be substantial, even with the use of hematopoietic growth factor support. It is apparent that new strategies of therapeutic intervention must be explored.
尽管霍奇金淋巴瘤（HD）通常与先天性或获得性免疫缺陷疾病无关，但最近的证据表明，感染人类免疫缺陷病毒（HIV）的个体患HD的比例在统计学上有显著增加。在存在潜在HIV感染的情况下，HD的临床和病理特征可能与通常预期不同。因此，70%-100%感染HIV的HD患者会出现全身性“B”症状。同样，约75%-90%的患者报告有播散性、III期或IV期疾病。骨髓是结外HD的常见部位，发生率为40%-50%。多药化疗后的完全缓解率约为45%至70%，尽管中位生存期仅约为18个月。即使使用造血生长因子支持，多药化疗引起的血液学毒性可能也很大。显然，必须探索新的治疗干预策略。
